What one share of Alzamend Neuro holds
We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”).
Alzamend Neuro’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Profit | −$2.31 |
|---|---|
| Cash and investments | $1.57 |
| Book value | $1.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$81.00 | — | — | — | $17.13 |
| 2021 | — | −$93.78 | — | — | — | $40.30 |
| 2022 | — | −$187.31 | — | — | — | $188.77 |
| 2023 | — | −$205.97 | — | — | — | $42.41 |
| 2024 | — | −$134.11 | — | — | — | −$33.94 |
| 2025 | — | −$11.32 | — | — | — | $5.10 |
| 2026 | — | −$2.63 | — | — | — | $0.17 |
Common questions about Alzamend Neuro
How much does one share of Alzamend Neuro earn?
Over the last 12 months, Alzamend Neuro lost $2.31 for each share.
Does Alzamend Neuro pay a dividend?
Alzamend Neuro didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Alzamend Neuro’s book value per share?
Alzamend Neuro’s book value is $1.20 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of July 31, 2026.
How much cash and debt does each share of Alzamend Neuro have?
Each share of Alzamend Neuro has $1.57 of cash and investments, as of July 31, 2026.
Has Alzamend Neuro bought back shares?
Alzamend Neuro’s share count rose about 6223% from 2020 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.